According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock reached 20% for three consecutive trading days from July 14 to 16, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders, there is no material information that should have been disclosed but not disclosed, other than matters that have already been disclosed. Currently, the company's production and operation are normal. No media reports or market rumors have been found to have a significant impact on the stock price. Relevant personnel did not trade the company's shares during the period of abnormal fluctuations. The company reminds investors to be aware of transaction risks.

According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock reached 20% for three consecutive trading days from July 14 to 16, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders, there is no material information that should have been disclosed but not disclosed, other than matters that have already been disclosed. Currently, the company's production and operation are normal. No media reports or market rumors have been found to have a significant impact on the stock price. Relevant personnel did not trade the company's shares during the period of abnormal fluctuations. The company reminds investors to be aware of transaction risks.